Human PD-1 Monoclonal Antibody
Product Sizes
1 mg
£486.00
YR0101-1MG
5 mg
£1355.00
YR0101-5MG
20 mg
£3531.00
YR0101-20MG
About this Product
- SKU:
- YR0101
- Additional Names:
- CD279|hPD-1|hPD-l|hSLE1|PD1|PDCD1|SLEB2
- Application:
- Block/Inhibit/Neutralise, Cell-based/Functional Assay, ELISA
- Clonality:
- Monoclonal
- Extra Details:
- Spartalizumab Biosimilar uses the same protein sequences as the therapeutic antibody spartalizumab. A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.
- Formulation:
- Purified from cell culture supernatant in an animal-free facility
- Immunogen:
- Human PD-1
- Isotype:
- IgG4, kappa
- Molecular Weight:
- 150 kDa
- Purity:
- >95%
- Shipping Conditions:
- Blue Ice
- Storage Conditions:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- ABclonal Technology
- Type:
- Antibody: Biosimilar Antibody
- Manufacturer's Data Sheet:YR0101
